Literature DB >> 1988515

Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.

E Azoulay-Dupuis1, J P Bedos, E Vallée, D J Hardy, R N Swanson, J J Pocidalo.   

Abstract

The efficacy of temafloxacin against Streptococcus pneumoniae in an experimental murine pneumonia model was compared with that of ofloxacin and ciprofloxacin. Erythromycin and amoxicillin were used as reference agents. Subcutaneous administration of antibiotics every 12 h for 3 days was initiated at various times after infection. The cumulative survival rates of mice treated with temafloxacin at 50 mg/kg were 100%, 92%, 81%, and 50% with treatment beginning 18, 48, 72, and 96 h after infection, respectively. The activity of temafloxacin at 50 mg/kg was not significantly different from that of erythromycin and amoxicillin but was superior to that of ofloxacin and ciprofloxacin. The maximum cumulative survival rates of mice treated with ofloxacin and ciprofloxacin at 100 mg/kg were 67% and 50%, respectively, with treatment beginning 18 h after infection. Treatment with ofloxacin and ciprofloxacin at 50 mg/kg 18 h after infection did not significantly increase survival rates compared with those of untreated controls.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988515     DOI: 10.1093/infdis/163.2.319

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  Novel bacterial NAD+-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivo.

Authors:  Scott D Mills; Ann E Eakin; Ed T Buurman; Joseph V Newman; Ning Gao; Hoan Huynh; Kenneth D Johnson; Sushmita Lahiri; Adam B Shapiro; Grant K Walkup; Wei Yang; Suzanne S Stokes
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

2.  Discovery of inhibitors of 4'-phosphopantetheine adenylyltransferase (PPAT) to validate PPAT as a target for antibacterial therapy.

Authors:  Boudewijn L M de Jonge; Grant K Walkup; Sushmita D Lahiri; Hoan Huynh; Georg Neckermann; Luke Utley; Tory J Nash; Jesse Brock; Maryann San Martin; Amy Kutschke; Michele Johnstone; Valerie Laganas; Laurel Hajec; Rong-Fang Gu; Haihong Ni; Brendan Chen; Kim Hutchings; Elise Holt; David McKinney; Ning Gao; Stephania Livchak; Jason Thresher
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

3.  Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.

Authors:  J P Bédos; V Rieux; J Bauchet; M Muffat-Joly; C Carbon; E Azoulay-Dupuis
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 4.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

5.  Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing.

Authors:  Delphine Croisier-Bertin; Lionel Piroth; Pierre-Emmanuel Charles; Aurélie Larribeau; Donald Biek; Yigong Ge; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

6.  Amoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics.

Authors:  Pierre Abgueguen; Esther Azoulay-Dupuis; Violaine Noel; Pierre Moine; Veronique Rieux; Bruno Fantin; Jean-Pierre Bedos
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

Review 7.  Quinolones in the treatment of lower respiratory tract infections in adult patients.

Authors:  C Carbon
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 8.  Animal models of Streptococcus pneumoniae disease.

Authors:  Damiana Chiavolini; Gianni Pozzi; Susanna Ricci
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

9.  In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia.

Authors:  E Azoulay-Dupuis; E Vallee; B Veber; J P Bedos; J Bauchet; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

10.  In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.

Authors:  Y Gohara; S Arai; A Akashi; K Kuwano; C C Tseng; S Matsubara; M Matumoto; T Furudera
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.